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BACKGROUND: This study was performed to test the hypothesis that expression of small heat shock protein Hsp-27 is, at diagnosis, a
reliable predictive biomarker of clinically aggressive prostate cancer.
METHODS: A panel of tissue microarrays constructed from a well-characterised cohort of 553 men with conservatively managed
prostate cancer was stained immunohistochemically to detect Hsp-27 protein. Hsp-27 expression was compared with a series of
pathological and clinical parameters, including outcome.
RESULTS: Hsp-27 staining was indicative of higher Gleason score (Po0.001). In tissue cores having a Gleason score 47, the presence
of Hsp-27 retained its power to independently predict poor clinical outcome (Po0.002). Higher levels of Hsp-27 staining were
almost entirely restricted to cancers lacking ERG rearrangements (w
2 trend¼31.4, Po0.001), although this distribution did not have
prognostic significance.
INTERPRETATION: This study has confirmed that, in prostate cancers managed conservatively over a period of more than 15 years,
expression of Hsp-27 is an accurate and independent predictive biomarker of aggressive disease with poor clinical outcome
(Po0.001). These findings suggest that apoptotic and cell-migration pathways modulated by Hsp-27 may contain targets susceptible
to the development of biologically appropriate chemotherapeutic agents that are likely to prove effective in treating aggressive
prostate cancers.
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Biologically and behaviourally, prostate cancer is a heterogeneous
malignant disease (Foster et al, 2002). In the USA, in 2008, there
were 186,320 new cases of prostate cancer and 28660 deaths from
this disease (Jemal et al, 2008). Equivalent figures from the United
Kingdom reveal that 34,302 new cases were diagnosed in 2005 and that
10000 men died of prostate cancer (http://info.cancerresearchuk.org/
cancerstats/types/prostate/). Globally, prostate cancer is currently
the fifth commonest malignancy and the most common in men,
with more than 679000 new cases estimated to have occurred in
2002 (Parkin et al, 2005). The clinical potential of an individual
prostate cancer may range from relative indolence to highly
aggressive, with progression occurring rapidly. Hence, there is an
urgent requirement to develop reliable biomarkers that can
accurately stratify prostate cancer at diagnosis and segregate
men with aggressive cancers requiring urgent treatment from
those who may be managed conservatively. Thus far, the only two
parameters generally accepted to be valuable in the clinical
management of prostate cancer are serum PSA and Gleason score
following histopathological assessment of prostatic biopsy speci-
mens. Although the extent of disease is more useful than clinical
stage at diagnosis, and retains a low level of significance in
multivariate analysis, neither of these are of clinical utility and are
significantly inferior to Gleason score and PSA (Cuzick et al, 2006).
Although both approaches have been clinically valuable, neither
provides accurate predictive information with respect to individual
prostate cancers.
Hsp-27 was originally discovered as an oestrogen-modulated
protein in breast cancer (Adams et al, 1983), and thereafter
identified to contribute to apoptosis (Tenniswood et al, 1992) and
as a potential prognostic marker in prostate cancer cells (Morino
et al, 1997). The functional relationship between Hsp-27, encoded
by the gene HSPB1 located on human chromosome 7 at q11.23, and
behavioural phenotype was suggested in the preliminary study that
showed Hsp-27 expression to predict (Po0.0001) death from
prostate cancer (Cornford et al, 2000). However, the cohort was
heterogeneous and the sample size relatively small. In contrast,
the current study has allowed a rigorous assessment of Hsp-27
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sexpression in a large cohort of well-characterised and conservatively
managed patients (Cuzick et al, 2006) with respect to the
prediction of tumour aggression. Our original observation that
Hsp-27 predicts clinical recurrence in prostate cancer was
supported by the finding from a subsequent study that the protein
level increases after androgen ablation and is cytoprotective in
hormone-refractory prostate cancer (Rocchi et al, 2004), and, more
recently, by two studies on men undergoing radical prostatectomy
(Glaessgen et al, 2008; Miyake et al, 2008).
The value of Hsp-27 expression as a predictive biomarker is not
restricted to prostate cancer. In developing breast neoplasia,
modulation of Hsp-27 in early proliferative lesions (O’Neill et al,
2003) occurs synchronously with that of ER-alpha to predict
subsequent development of breast malignancy (Po0.001). How-
ever, in established node-positive breast cancer, Hsp-27 does not
predict survival (Tetu et al, 1995). In cervical neoplasia, association
has been reported between over-expression of Hsp-27 and grade,
although no survival data were included (Ono et al, 2009). With
respect to treatment of malignant disease, increased expression of
Hsp-27 has been linked to vincristine resistance in gastric cancer
(Yang et al, 2009) and to 5-fluorouracil resistance in colon cancer
(Tsuruta et al, 2008), and breast cancer cells initially over-
expressing Hsp-27 became sensitive to doxorubicin after modula-
tion of endogenous Hsp-27 levels by paclitaxel (Shi et al, 2008).
Prostate cancers often contain an ETS-gene fusion that involves
the androgen-regulated promoter regions from the TMPRSS gene
(chromosome 21q22.3) and joins to 30 ERG sequences (Tomlins
et al, 2005). These translocations are common in established
prostate cancer (Clark et al, 2007, 2008) and have been identified in
PIN, but with a lower frequency (Cerveira et al, 2006; Perner et al,
2007; Mosquera et al, 2008). Taken together with evidence from
transgenic mouse studies (Tomlins et al, 2008), these observations
suggest that TMPRSS–ERG fusion alone may be insufficient for
transformation from benign to malignant prostatic epithelium.
However, the biological activity of alternatively spliced TMPRSS2–
ERG fusion gene transcripts is pleiotropic (Wang et al, 2008), with
the consequential effects on the emerging phenotypes of the
involved neoplastic cells (initiation vs progression) depending on
the corresponding rearrangement (Carver et al, 2009).
To test the hypothesis that Hsp-27 expression is a reliable
predictive biomarker of clinically aggressive prostate cancer, we
analysed an extensive set of tissue microarrays (TMAs) con-
structed from the archived diagnostic tissues obtained by the
Transatlantic Prostate Group following interrogation of 6 UK
Cancer Registries (Cuzick et al, 2006). This cohort of patients, with
a detailed clinical follow-up extending over 15 years, has provided
an opportunity to assess the time over which Hsp-27 expression
might have predictive accuracy. As we had already utilised this
cohort to confirm the predictive power of ETS-gene alterations, we
were able to assess the relationship between ETS-gene status and
Hsp-27 expression.
MATERIALS AND METHODS
Patient cohort
To help identify and optimise markers that may be of use in the
treatment of men with prostate cancer, we recently established a
retrospective cohort of men who were managed only conserva-
tively (Cuzick et al, 2006; Eastham et al, 2008). Improving on
previous studies (Chodak et al, 1992; Albertsen et al, 1995, 2005;
Adolfsson et al, 1997; Holmberg et al, 2002; Johansson et al, 2004;
Bill-Axelson et al, 2005), our analyses included centrally assigned
Gleason scores determined by modern grading criteria and allowed
comparisons with several additional clinical parameters. In
agreement with Johansson et al (2004) and Albertsen et al
(2005), we found Gleason score to be an important determinant
of cancer-specific mortality, but baseline PSA and, to a lesser
extent, stage of disease added further predictive value. Tissue
microarrays were constructed from an unselected transurethral
resection of the prostate specimens taken from patients who had
received no initial treatment in a cohort of conservatively managed
men with prostate cancer. Men who had had hormone therapy
before diagnostic biopsy were also excluded, because of the
influence of hormone treatment in the interpretation of Gleason
grade (Cuzick et al, 2006).
Tissue micro-arrays for Hsp-27 analysis and for ETS-rearrangement
FISH studies The original haematoxylin and eosin (H&E)-stained
diagnostic tissues for all cases included in this study were reviewed
by a panel of three urological pathologists (DMB, CSF and VER) as
previously described to confirm each diagnosis of prostate cancer
and to exclude all false positives (Berney et al, 2007b). Of the total
number of cases reviewed, 133 (7%) were reassigned a non-
malignant diagnosis and thereafter excluded. The remaining 1656
cases were further reviewed to confirm and standardise the
Gleason score according to conventional criteria (Deshmukh and
Foster, 1997). For those 1656 cases of cancer, there was a
significant reassignment in the Gleason score across a wide
spectrum, yielding a more accurate predictor of prognosis than the
original scores in multivariate analysis (Berney et al, 2007a).
Following mark-up of the tissue sections to identify the
predominant patterns of prostate cancer and of non-malignant
glandular epithelium, TMAs were constructed in 35 22 7mm
3
blocks of Lamb paraffin wax using a manual tissue microarrayer
(Beecher Instruments, Sun Prairie, WI, USA). Up to four cores of
600mm diameter were taken from each prostatic tissue. Reassign-
ment of areas of cancer or non-malignant epithelium in each core
was performed by histopathological examination of H&E- and p63/
AMACR-stained sections that flanked the TMA slice used for FISH
studies. The morphological criteria for selection of ‘normal’ and
‘malignant’ prostatic epithelium conformed to previously pub-
lished definitions (Foster, 2000; Foster et al, 2000, 2004). FISH
studies to detect ERG and ETV1 gene re-arrangements were
conducted as described previously (Attard et al, 2008a,b).
Ethical approval Approval for the collection of the cohort was
obtained from the Northern Multi-Research Ethics Committee,
followed by approval from the local ethics committee at each of the
collaborating hospital trusts. This work was approved by the
Clinical Research and Ethics Committee at the Royal Marsden
Hospital and The Institute of Cancer Research.
Hsp-27 immunohistochemistry A mouse monoclonal antibody to
Hsp-27 was purchased from Leica Microsystems (NCL-Hsp-27 –
Leica Microsystems Newcastle Ltd, Newcastle Upon Tyne, UK).
The ADVANCE Autostainer Universal Staining System, rabbit/
mouse HRP was purchased from Dako (K4068, Dako UK Ltd, Ely,
Cambridge, UK). High-temperature antigen retrieval was per-
formed using a domestic stainless-steel pressure cooker at full
pressure for 3min in 10mM EDTA solution (pH 7.0). The Hsp-27
antibody was diluted in REAL Antibody Diluent (S2022, Dako UK
Ltd) to 1:50. Sections of each specimen, of 4mm thickness, were
cut onto amino-propyl tri-ethoxysilane-coated glass slides and
dried overnight in an oven at 561C. For staining, slides were
dewaxed with xylene, followed by rehydration through graded
ethanols. Endogenous peroxidase activity was blocked by immer-
sion in a 3% (w/v) solution of H2O2 in methanol for 12min.
Sections were then rinsed in tap water followed by deionised water.
High-temperature antigen retrieval was performed, after which
slides were transferred to an automatic immunostainer
(Autostainer Plus, Dako UK Ltd). After equilibration in fresh TBS
comprising 0.05 M Tris (pH 7.6) containing 0.12 M NaCI and 0.05%
Tween-20 (TBS-T), sections were incubated with the primary
antibody for 40min at room temperature, washed with TBS-T and
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sincubated with ADVANCE link reagent for 20min at room
temperature, washed with TBS-T and incubated with ADVANCE
enzyme reagent for 30min at room temperature. Thereafter,
sections were washed before applying a solution of 3,30-diamino-
benzidine tetrahydrochloride and H2O2 (DABþ, K3468, Dako UK
Ltd) for 10min to reveal sites of antibody binding. Following a
rinse in deionised water, slides were removed from the Auto-
stainer. Nuclei were counterstained with Mayer’s haematoxylin
before mounting the slides in DPX. For the negative control used
in each experiment, the primary antibody was replaced with
Antibody Diluent. All sections were scored using CSF and ARD.
Analysis of Hsp-27 expression Specimens were considered
positive only if at least 5% of the epithelial cells (either normal
or malignant) unequivocally expressed Hsp-27 staining. The 5%
cut-off was chosen because it conforms to the International
European Organization for Research and Treatment of Cancer-
Gynaecological Cancer Cooperative Group recommendations (van
Diest et al, 1997). Furthermore, this cut-off was used as the
criterion to distinguish positive and negative immunohistochemical
staining in our previous studies of prostate cancer (Cornford et al,
2000), thus ensuring consistency of criteria between studies. For
each tissue section, staining was assessed as negative, weakly
positive or only focally positive (low-level expression), or strongly
positive (high-level expression), and scored as 0, 1, 2 or 3,
respectively. For positive cores, the cellular distribution of Hsp
staining in benign or malignant prostatic epithelium was assessed.
Statistical analyses The primary end points for this study were
time to death from prostate cancer and time to death from any
cause. Univariate and multivariate analyses were performed by
proportional hazard (Cox) regression analysis (Cox and Oakes,
1984). All follow-up times commenced at the point of 6 months
following diagnosis, as in the previous report (Cuzick et al, 2006).
Associations between categorical data were examined using the
w
2 test and Fisher’s exact test when expected cell counts were less
than 5. Associations between categorical and numerical variables
were assessed using analysis of variance. All P-values were two-
sided. The following variables, determined as described previously
(Cuzick et al, 2006), were included in the multivariate analyses:
centrally reviewed Gleason score, baseline PSA (the last PSA value
within 6 months of diagnosis) and age at diagnosis. Clinical stage
information, which was available for 60% of the patients, was of
minimal significance in this restricted series and was therefore not
included.
RESULTS
Hsp-27 expression in prostate tissue
Analysis of the cores of tissues contained in the 24 blocks
comprising the arrays showed that 743 patients were represented
on the arrays that included 1251 cancer cores, 18 PIN, 624 non-PIN
hyperplasia and 792 cores with morphologically benign tissues.
The distribution of cytoplasmic Hsp-27 expression within the
various morphological groups ranging from benign to malignant is
presented in Figure 1. In this analysis, Hsp-27 expression was
identified in 64% of the cores containing morphologically
unremarkable prostatic epithelia, and in 50% of the cores of
hyperplastic tissues (Figure 2). Of the 18 PIN cores only 7 (39%)
were positive, while 200 (16%) of the prostate cancer cores were
positive. When the data for the malignant tissues were analysed
with respect to individual cases, 553 patients remained in the
analysis, with 441 (79.7%) of the cases being negative for Hsp-27
and 112 (20.3%) of the cases showing cytoplasmic positivity. The
patients’ demographics and tumour characteristics, together with
details of their Hsp-27 expression, are presented in Table 1. Hsp-27
expression was associated with Gleason score (P¼0.001), whereas
no association was found with age, baseline PSA, clinical stage or
extent of disease.
Overall effect of Hsp-27 Absence of Hsp-27 expression was
associated with a better survival from prostate cancer (Figure 3)
and overall survival. In the univariate analyses, Hsp-27 cytoplas-
mic positivity was a significant prognostic factor for poor survival
from prostate cancer (HR¼1.89, 95% CI¼1.32–2.70, Po0.001)
and overall survival (HR¼1.60, 95% CI¼1.26–2.05, Po0.001). In
multivariate analyses that included Gleason score, extent of
disease, baseline PSA and age at diagnosis, Hsp-27 cytoplasmic
positivity remained an independent prognostic factor for poor
cancer-specific survival (Dw
2(1df)¼4.49, P¼0.03) and overall
survival (Dw
2(1df)¼7.45, P¼0.005).
Subgroup analyses
Analysis of Hsp-27 expression according to Gleason score: The
independent prognostic significance of Hsp-27 cytoplasmic
positivity for prostate cancer survival in a multivariate model
was maintained in prostate cancers with Gleason score 47
(Dw
2(1df)¼7.08, P¼0.03 for prostate cancer survival), but not
in prostate cancers with Gleason score 7 (Dw
2(1df)¼0.43, P¼0.50)
or in prostate cancers with Gleason score o7( Dw
2(1df)¼0.11,
P¼0.75), as shown schematically in Figure 4.
Analysis of Hsp-27 expression according to ETS-re-arrangement
status: Both Hsp-27 expression and ETS (ERG and ETV1) gene
status were available for 435 of the 553 patients (Table 2). When
the cancers were stratified according to ETS-gene status, in
multivariate analyses the presence of Hsp-27 cytoplasmic positivity
failed to reach significance for prostate cancer survival in both
non-rearranged ETS (Dw
2(1df)¼2.35, P¼0.12) and rearranged
ETS status (Dw
2(1df)¼0.68, P¼0.40) groups. However, interroga-
tion of the data (Table 2) revealed a significant difference in the
distribution of Hsp-27 staining in the two groups (w
2¼18.3,
Po0.001). With increasing expression of Hsp-27 there was a
progressive decline in ETS-gene rearrangement frequency
(w
2(trend)¼31.4, Po0.001), such that most of the strongly
staining cancers were found in ERG non-rearranged tumours.
DISCUSSION
This study has shown that, at diagnosis, Hsp-27 expression is a
powerful independent predictive biomarker for survival from
prostate cancer (Po0.001) and for overall survival (Po0.001).
Using a large cohort of men gathered from across the United
Kingdom over a period of more than 15 years, Hsp-27 expression
was used to accurately segregate men with poor prognosis of
prostate cancer and who required active treatment from those with
relatively indolent disease that could be managed conservatively,
with confidence. In this study, Hsp-27 expression correlated
strongly with Gleason grade (P¼0.001), but not with baseline PSA
values (P40.2), despite PSA being an independent predictive
variable in the original cohort of patients. The latter observation
reflects the complex relationships between Hsp-27 and androgen
receptor in the transactivation of PSA (Zoubeidi et al, 2007). The
current findings also reveal that while most morphologically
benign tissues strongly express Hsp-27, lower proportions of
hyperplasia and PIN exhibit staining (Figure 1), suggesting that
expression of the protein may be down-regulated in the in-situ
neoplastic epithelial cells, which are the precursors of invasive
prostate cancer (Foster et al, 2002).
There is strong evidence that Hsp-27 is an important gatekeeper
of cancer cell migration and survival through differential
phosphorylation and by its relative level of expression. Evidence
from different cell systems indicates that Hsp-27 controls cell
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slocomotion by a common mechanism. In fibroblasts (Hirano et al,
2004), endothelium, neutrophils and epithelial cells, phosphoryla-
tion and polymerisation of Hsp-27 modulates transformation of
G-F actin (Tak et al, 2007) to generate the mechanical force
required for cell motility to occur through organisation of
cytoskeletal components (Doshi et al, 2009). In endothelial cells,
Hsp-27 co-localises with and regulates assembly of actin filaments
following phosphorylation by p38 MAP kinase (Guay et al, 1997;
Landry and Huot, 1999). Thereafter, the phosphorylated and non-
phosphorylated forms of Hsp-27 become differentially distributed
throughout the lamellipodia, which, in the presence of fascin
(Vignjevic et al, 2006), enable cell migration (Nagy et al, 2008).
Non-phosphorylated Hsp-27, excluded from the leading edge of
the lamellipodia, maintains short-branched actin molecules,
whereas phosphorylated Hsp-27 at the base of the lamellipodia
stabilises actin networks composed of long unbranched filaments
(Pichon et al, 2004). When Hsp-27 phosphorylation is inhibited
and functional interaction with actin impaired, migration depen-
dent on F-actin polymerisation is prevented (Chen et al, 2009).
Enhanced levels of Hsp-27, together with its relocation from the
cytoplasm to the nucleus (Wissing and Jaattela, 1996), is associated
with increased resistance to apoptosis (Samali and Cotter, 1996).
However, inhibition of apoptosis by Hsp-27 involves at least two
parallel pathways. In the first, phosphorylated dimers of Hsp-27
interact with Daxx and block Fas-mediated apoptosis, but with no
effect on Fas-induced FADD and caspase-dependent apoptosis
(Charette et al, 2000). In the second, following interaction of
AB C D
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Figure 1 Immunohistochemical expression of Hsp-27 in TMA cores of prostatic tissues. The location of the high-magnification regions shown below each
of the cores is indicated by the corresponding rectangular field. Stromal expression was not identified in any of the malignant tissues examined. No
expression of Hsp-27 was identified in the nuclei although the amounts may be below the level of immunohistochemical detection. (A) Normal prostatic
tissue in which luminal epithelial cells express Hsp-27 within the cytoplasm. Basal cells are scanty but, where present, are also stained. Stromal tissues are not
stained. (B) Hyperplastic but not dysplastic glandular epithelium strongly expressing Hsp-27 within the cytoplasm. (C) Hyperplastic and mildly dysplastic
epithelium in which basal cells are prominent and uniformly express Hsp-27. The overlying luminal epithelial cells are mainly negative, although a few express
Hsp-27 strongly. (D) Hyperplastic, dysplastic and focally neoplastic intra-glandular epithelium that is predominantly negative for Hsp-27. Occasionally small
foci of basal and luminal epithelial cells strongly express Hsp-27. (E) Moderately differentiated (Gleason 3þ3) prostatic adenocarcinoma that is negative for
Hsp-27 expression. (F) Moderately differentiated (Gleason 3þ3) prostatic adenocarcinoma expressing Hsp-27 at a low level (þ) in the cytoplasm of the
majority of the malignant cells. (G) Poorly differentiated (Gleason 4þ3) prostatic adenocarcinoma expression of Hsp-27 at a high (þþþ) level in the
cytoplasm of the majority of the malignant cells. (H) Very poorly differentiated (Gleason 5þ5) prostatic adenocarcinoma heterogeneously expressing Hsp-
27 at an intermediate level (þþ) in the majority, but not all of the malignant cells. Magnification of all cores:  60. The detailed fields within each of the
cores are magnified at  200.
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Figure 2 Numerical distribution of Hsp-27 expression by the epithelial
cells in normal, hyperplastic, PIN and malignant tissues (cancer cores). The
clinical behaviour of the malignant cells expressing Hsp-27 is shown in
Figure 3. The þ, þþ and þþþ signs are a conventional semi-quantitative
assessment of the amount of staining defined in Figure 1 legend.
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sphosphorylated Hsp-27 with the cytochrome c/Apaf-1/dATP
complex, the Fas-adaptor FADD down-regulates the procaspase
9-dependent apoptotic pathway (Gibbons et al, 2000; Jolly and
Morimoto, 2000; Charette et al, 2001). In the prostate, down-
regulation of apoptosis is associated with elevated levels of Hsp-27,
such that PC-3 and LNCaP cells become resistant to both chemical-
and radiation-induced apoptosis (Gibbons et al, 2000; Jolly and
Morimoto, 2000).
In non-malignant cells Hsp-27 is phosphorylated by MAP kinase
p38 (Rouse et al, 1994; Huot et al, 1995), thus maintaining cellular
homeostasis and integrity. Thereafter, Hsp-27 exists in an auto-
phosphorylating signal complex together with Akt, p38 MAPK and
MK2, in which Akt becomes phosphorylated on Ser
473 by MK2
(Wu et al, 2007). When Hsp-27 dissociates from the complex
before Akt activation, apoptosis is induced. In androgen-
independent prostate cancer, lethal progression is associated with
reduced apoptosis (Berges et al, 1995) and enhanced tumour cell
proliferation (McLoughlin et al, 1993; Berney et al, 2009).
Mechanistically, Hsp-27 activity is regulated by post-translational
phosphorylation at serine residues Ser
15, Ser
78 and Ser
82 and at
theonine residue Thr
143 (Landry et al, 1992). However, this process
appears to be promiscuous in cancer cells, being dependent on the
particular kinase activation pathway invoked and the individual
cell system involved. In response to extra- or intra-cellular
information, signal transducer Stat 3, controlled by its inhibitor
DIAS3, alters genomic expression of Hsp-27 and facilitates
phosphorylation at Ser
78 (Song et al, 2004).
Comparison of the distribution and intensity of Hsp-27
expression with ETS status (Clark et al, 2007, 2008; Attard et al,
2008a,b) has confirmed a statistically significant (P40.001)
inverse relationship between these two parameters. As the
numbers of cancers containing Ets rearrangements were similar
to the numbers with Ets non-rearranged in the Hsp-27-negative
group, but declined rapidly with increasing expression of Hsp-27
(Table 2), it is possible that strong expression of Hsp-27 might
prevent subsequent rearrangement of Ets genes if these occur
subsequent to changes in Hsp-27. With respect to behavioural
phenotype, strong expression of Hsp-27 and ETS-gene rearrange-
ment are each independently associated with aggressive and
rapidly lethal prostate cancer.
Not only is Hsp-27 a powerful biomarker of aggressive prostate
cancer, but it is also a potential target for novel therapeutic
intervention. Studies involving antisense oligonucleotides or
siRNA gene knockdown showed that Hsp-27 expression promotes
androgen-independent progression of prostate cancer (Rocchi
et al, 2004, 2005). Inhibition of HSPB1 expression modulated
apoptosis and abrogated the malignant phenotype of human
prostate cancer cells, thus identifying Hsp-27 as a potential
therapeutic target. Separately, the biphenyl isoxasole KRIBB3
inhibits tumour cell migration by blocking protein kinase
C-dependent phosphorylation of Hsp27 (Shin et al, 2005) to
induce mitotic arrest and to enhance apoptosis (Shin et al, 2008).
Recently, it has been shown that pyrrolo-pyrimidones, a novel
class of p38 MAPK/MAPK-activated protein kinase 2 (MK2)
Table 1 Relationship of Hsp-27 level with demographics and tumour
characteristics
Hsp-27 expression
Variable
Total
(n¼553)
Negative
(n¼441)
Positive
(n¼112) P-value
Mean age±s.d. (years) 69±56 9 ±57 0 ±5 0.43
Mean follow-up±s.d.
(months)
95±49 99±48 82±47 o0.001
Early hormone management 0.21
Yes 119 90 (76%) 29 (24%)
No 434 351 (81%) 83 (19%)
Gleason score 0.001
o7 244 212 (87%) 32 (13%)
¼7 158 120 (76%) 38 (24%)
47 151 109 (72%) 42 (28%)
Clinical stage
a 0.78
T1 144 110 (76%) 34 (24%)
T2 134 107 (80%) 27(20%)
T3 69 52 (77%) 15 (23%)
Unknown 206 171 (83%) 35 (17%)
Baseline PSA (ngml
 1) 0.22
p4 173 147 (85%) 26 (15%)
44–10 102 76 (75%) 26 (25%)
410–25 120 97 (81%) 23 (19%)
425–50 95 73 (77%) 22 (23%)
450–100 63 48 (76%) 15 (24%)
Cancer in biopsy (%)
b 0.13
p6 123 104 (85%) 19 (15%)
46–20 139 110 (79%) 29 (21%)
420–40 79 68 (86%) 11 (14%)
440–75 83 62 (75%) 21 (25%)
475–100 122 91 (75%) 31 (25%)
Unknown 7 6 (86%) 1 (14%)
Abbreviation: PSA¼prostate-specific antigen.
aRelationship with Hsp-27 calculated
for patients with available clinical stage.
bRelationship with Hsp-27 calculated for
patients with available percentage of cancer in biopsy.
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Figure 3 (A) Prostate cancer survival and (B) overall survival according
to Hsp-27 expression.
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sinhibitors, inhibit phosphorylation of Hsp-27, its downstream
target (Schlapbach et al, 2008), and that inhibition of Hsp-27
phosphorylation at Ser
78 and Ser
82 by the MAPKAP kinase MK5
prevents the F-actin reorganisation that is necessary for cell
migration (Kostenko et al, 2009). Not only is the MAPKAPK2/
Hsp-27 pathway a promising potential target for therapeutic
intervention, but the isoflavone genistein, an oestrogen analog
and candidate chemotherapeutic agent, inhibits cell migration
by blocking activation of this pathway (Xu and Bergan,
2006), emphasising the validity of this proposed therapeutic
approach.
This study analysing the largest cohort yet reported of
conservatively managed patients with prostate cancer for more
than 15 years has shown the accuracy of Hsp-27 expression as a
prognostic biomarker of aggressive disease at initial diagnosis.
Further, the analysis indicates two divergent phenotypes of lethal
prostate cancer involving either ETS rearrangement or high Hsp-27
expression. These findings are of biological interest not only for
studying the initiation and progression of prostate cancer but also
for clinically identifying men who require immediate aggressive
management to control potentially lethal disease. As this is a
relatively small subset (B25–35%) of men diagnosed with
prostate cancer, use of this biomarker provides the biological
rationale to focus the available resources on actively treating this
high-risk group, while allowing the majority of prostate cancer
patients (B65–75%) to be managed conservatively.
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